CareDx, Inc 8-K

Summary

Q3 2026 results and raised FY2026 guidance. Revenue grew 39% Y/Y, driven mainly by Testing Services, including Specialty Oncology following the NavDx acquisition, and growth in Patient and Digital Solutions; adjusted EBITDA doubled to $30M. CareDx raised its FY2026 revenue and adjusted EBITDA outlooks and posted an updated corporate presentation current as of 9/30/2026.

Key Figures

• Testing Services revenue was $119M, +65% Y/Y, on approximately 75,900 tests, +51% Y/Y; the quarter included $12M of Specialty Oncology revenue. Excluding revenue from tests performed in prior periods, Testing Services revenue increased approximately 58% Y/Y. Patient and Digital Solutions revenue was $20.2M, +31% Y/Y, driven primarily by CareDx Pharmacy services.
• Adjusted EBITDA was $30.5M vs $15.3M, with a 22% margin vs 15%; the company attributed the increase to revenue growth, higher gross profit and disciplined operating expense management. Cash and cash equivalents were $250M at 9/30/2026, vs $65.4M at 12/31/2025.
• CareDx closed its acquisition of Naveris on 7/1/2026 for $160M in cash, plus up to $100M in contingent consideration. It also reported more than 5,000 transplant patients registered for its new patient portal, continued Epic Aura adoption, and migration of NavDx to its billing platform. AlloHeme is planned for commercial launch in Q1 2027 and HistoMap Kidney for broader commercial availability in 2027; both programs target readiness under the Clinical Laboratory Improvement Amendments before year-end.

Guidance

Guidance changes, derived from earlier filings

Metric	Period	Earlier guidance	Guidance now	Change
Revenue	FY2026	$490M-$500M	$520M-$530M	raised
Adjusted EBITDA, non-GAAP	FY2026	$66M-$78M	$90M-$100M	raised

Investor Takeaways

• Track whether Testing Services volume and revenue growth excluding prior-period test revenue continue, alongside growth in patient portal registrations; sustained progress would support the company’s reported demand and adoption trends.
• Watch for the stated year-end readiness targets for AlloHeme and HistoMap Kidney, followed by AlloHeme’s planned Q1 2027 launch and broader HistoMap Kidney availability in 2027.